The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

Abnormalities of the vitreoretinal interface may contribute to important retinal pathologies such as diabetic ... treatment option currently available is vitrectomy. Pharmacologic treatment ...

Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Several factors, including the increasing prevalence of eye disorders such as cataracts, glaucoma, diabetic retinopathy ... patient knowledge about treatment options, including ophthalmic laser ...

The mean BCVA improvement from nadir (the worst recorded vision) was −0.4 logMAR (+4 lines on the Early Treatment Diabetic Retinopathy ... with few treatment options. Future studies should ...